Quest PharmaTech Inc.
QPTFF
Rank in Stocks
#30452
Quest PharmaTech Inc. (QPTFF), an Edmonton, Canada-based pharmaceutical firm,... Quest PharmaTech Inc. (QPTFF), an Edmonton, Canada-based pharmaceutical firm, specializes in creating antibody-driven immunotherapeutic remedies primarily for various cancers. A cornerstone of its product pipeline is Mab AR 9.6, an advanced therapeutic candidate specifically designed to target truncated O-glycans on MUC16 for precise cancer treatment applications. The company's offerings further encompass Oregovomab, an anti-CA-125 antibody that has successfully completed Phase II clinical trials for the management of ovarian cancer. Beyond these specific agents, Quest PharmaTech is actively involved in the development, manufacturing, and commercialization of new immunotherapy products aimed at combating pancreatic cancer. The organization also diversifies its portfolio by utilizing proprietary transdermal delivery technologies to formulate products for dermatological conditions and wound healing. Additionally, it develops specialized skin-penetrating active molecules for use in both cosmetic and pharmaceutical goods. Rounding out its innovative efforts, Quest PharmaTech designs intricate combinatorial immunotherapies for cancer, employing monoclonal antibodies belonging to both immunoglobulin G and E classes.
Share Price
$0.03
Last synced: 2026-11-10
Market Cap
$5.07M
Change (1 day)
0.00%
Change (1 year)
125.56%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Quest PharmaTech Inc. (QPTFF)
Category
Healthcare
Operating Margin for Quest PharmaTech Inc. (QPTFF)
Operating Margin as of November 2026 TTM: 0.00%
According to Quest PharmaTech Inc.'s latest financial reports, its current operating margin (TTM) is 0.00%. At the end of 2025 the company had an operating margin of 0.00%.
Operating Margin history for Quest PharmaTech Inc. from 2001 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | 0.00% | 0.00% |
| 2025 | 0.00% | 0.00% |
| 2024 | 0.00% | 0.00% |
| 2023 | 0.00% | 0.00% |
| 2022 | 0.00% | 0.00% |
| 2021 | 0.00% | 0.00% |
| 2020 | 0.00% | 0.00% |
| 2019 | 0.00% | 0.00% |
| 2018 | 0.00% | -100.00% |
| 2017 | -168,036.55% | 0.00% |
| 2016 | 0.00% | 0.00% |
| 2015 | 0.00% | -100.00% |
| 2014 | -8.55% | -99.40% |
| 2012 | -1,436.96% | -91.11% |
| 2011 | -16,162.50% | 23,922.74% |
| 2010 | -67.28% | 356.45% |
| 2009 | -14.74% | -93.60% |
| 2008 | -230.43% | -99.66% |
| 2007 | -66,909.56% | 3,371.55% |
| 2005 | -1,927.37% | -22.66% |
| 2004 | -2,492.22% | 131.56% |
| 2003 | -1,076.27% | 135.91% |
| 2002 | -456.23% | -23.29% |
| 2001 | -594.76% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | - |
US
|
|
| -149.01% | - |
US
|
|
| 25.57% | - |
AU
|
|
| 31.23% | - |
BE
|
|
| 29.35% | - |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Quest PharmaTech Inc.'s operating margin
What was Quest PharmaTech Inc.'s operating margin in 2025?
In 2025, Quest PharmaTech Inc.'s operating margin was 0.00%, compared with 0.00% in 2024.
How has Quest PharmaTech Inc.'s operating margin changed since 2020?
From 2020 to 2025, Quest PharmaTech Inc.'s operating margin was highest in 2025 (0.00%) and lowest in 2025 (0.00%).
How does Quest PharmaTech Inc.'s operating margin compare with similar companies?
Quest PharmaTech Inc.'s operating margin (0.00%) is higher than that of 1 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.